Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07441642 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
A Phase 2 study of Geographic Atrophy Secondary to Age-related Macular Degeneration, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 272
- Enrollment target
- 4
- Study locations
NCT07441642 is a Phase 2 study of Geographic Atrophy Secondary to Age-related Macular Degeneration that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 272 participants, above the 158-participant average among 4 other Geographic Atrophy Secondary to Age-related Macular Degeneration trials with a reported enrollment target (72% higher). The trial reports 4 study locations across 3 states.
The verdict
NCT07441642, a Phase 2 study of Geographic Atrophy Secondary to Age-related Macular Degeneration, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 272 participants
- Enrollment target
- 4
- Study locations
Study Summary
To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG FWY003
Study Locations (4)
Florida
- Advanced Research LLC - Boynton Beach
- Advanced Research LLC - Deerfield Beach
California
- Salehi Retina Institute - Huntington Beach
Massachusetts
- Opthamalic Consultants of Boston - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2026-03-09 |
| Est. Completion | 2029-08-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07441642
The ClinicalTrials.gov registry entry for NCT07441642 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 158-participant average among 4 other Geographic Atrophy Secondary to Age-related Macular Degeneration trials with a reported enrollment target (72% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Geographic Atrophy Secondary to Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07441642 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Florida, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07441642 about?
NCT07441642 is a clinical study titled "A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration". To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
What is the current status of trial NCT07441642?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 272 participants. The study started on 2026-03-09. Estimated completion is 2029-08-22.
What conditions does trial NCT07441642 study?
This clinical trial studies the following conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration.
What interventions are being tested in trial NCT07441642?
The interventions under investigation include: Placebo (DRUG), FWY003 (DRUG).
Who is sponsoring clinical trial NCT07441642?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07441642 being conducted?
This trial has 4 study locations across California, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy Secondary to Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
RECRUITING · Phase 2
-
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
RECRUITING · Phase 2
-
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
RECRUITING · Phase 1
-
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.